Should I buy or sell Capricor Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CAPR shares. View CAPR analyst ratings or view top-rated stocks .

What is Capricor Therapeutics' stock price target for 2024?

2 brokerages have issued 1-year target prices for Capricor Therapeutics' stock. Their CAPR share price targets range from $8.00 to $40.00. On average, they predict the company's share price to reach $24.00 in the next year. This suggests a possible upside of 379.0% from the stock's current price. View analysts price targets for CAPR or view top-rated stocks among Wall Street analysts .

How have CAPR shares performed in 2024?

Capricor Therapeutics' stock was trading at $4.89 at the beginning of the year. Since then, CAPR stock has increased by 2.5% and is now trading at $5.01. View the best growth stocks for 2024 here .

When is Capricor Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CAPR earnings forecast .

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) released its earnings results on Thursday, February, 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.21. The biotechnology company had revenue of $12.09 million for the quarter, compared to analyst estimates of $5.80 million. Capricor Therapeutics had a negative net margin of 88.52% and a negative trailing twelve-month return on equity of 299.67%.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Vaxart (VXRT) , Inovio Pharmaceuticals (INO) , Trevena (TRVN) , Dynavax Technologies (DVAX) , Chesapeake Energy (CHKAQ) , OPKO Health (OPK) and Advanced Micro Devices (AMD) .

How do I buy shares of Capricor Therapeutics?

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CAPR

Capricor Therapeutics (CAPR) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free CAPR Stock Alerts

$5.01

-0.04 (-0.79%)

(As of 04/19/2024 ET)

Compare

Today's Range: $4.87
▼
$5.28
50-Day Range: $3.61
▼
$7.10
52-Week Range: $2.68
▼
$8.22

Volume: 354,006 shs
Average Volume: 286,540 shs
Market Capitalization: $157.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.00

Get Capricor Therapeutics alerts:

Capricor Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 379.0% Upside
$24.00 Price Target
Short Interest: Bearish
11.11% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.83) to $0.12 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.80 out of 5 stars

Medical Sector

832nd out of 911 stocks

Pharmaceutical Preparations Industry

375th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Capricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Capricor Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.11% of the outstanding shares of Capricor Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Capricor Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.
Change versus previous month
Short interest in Capricor Therapeutics has recently increased by 8.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Capricor Therapeutics does not currently pay a dividend.
Dividend Growth
Capricor Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CAPR.

1.4

News and Social Media Coverage

News Sentiment
Capricor Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Capricor Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.00% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 21.68% of the stock of Capricor Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($0.83) to $0.12 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Capricor Therapeutics is -5.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Capricor Therapeutics is -5.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Capricor Therapeutics has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Here’s how to start a “Weekend Side Hustle” from your sofa

Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.

Weekend after weekend!

About Capricor Therapeutics Stock (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

CAPR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CAPR Stock News Headlines

April 19, 2024 | markets.businessinsider.com

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

April 17, 2024 | americanbankingnews.com

Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above 50-Day Moving Average of $5.44

April 20, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

April 10, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know

April 3, 2024 | investing.com

Capricor Therapeutics Inc (CAPR)

March 21, 2024 | globenewswire.com

Capricor Therapeutics to Present at Upcoming Investor Conferences

March 19, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial Prospects

March 14, 2024 | finance.yahoo.com

Earnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

April 20, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

March 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Lineage Therap’s Growth and Innovation Poised to Transform Biotech Landscape

March 6, 2024 | markets.businessinsider.com

Capricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical Progress

March 6, 2024 | globenewswire.com

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 3, 2024 | finance.yahoo.com

Capricor Therapeutics Full Year 2023 Earnings: Beats Expectations

March 3, 2024 | seekingalpha.com

Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript

March 1, 2024 | finance.yahoo.com

Q4 2023 Capricor Therapeutics Inc Earnings Call

February 29, 2024 | benzinga.com

Recap: Capricor Therapeutics Q4 Earnings

February 29, 2024 | finance.yahoo.com

Capricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapy

February 29, 2024 | globenewswire.com

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 28, 2024 | benzinga.com

Capricor Therapeutics's Earnings Outlook

February 28, 2024 | markets.businessinsider.com

Capricor Therapeutics is about to announce earnings — here's what Wall Street expects

February 27, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Rocket Pharmaceuticals (RCKT)

February 27, 2024 | markets.businessinsider.com

Capricor Therapeutics Granted Type-B Meeting With FDA For CAP-1002 Muscular Dystrophy Drug, Stock Up

February 27, 2024 | marketwatch.com

Capricor Therapeutics Shares Rise 8% After FDA Meeting Set

February 27, 2024 | globenewswire.com

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

February 22, 2024 | finance.yahoo.com

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

February 22, 2024 | globenewswire.com

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

See More Headlines

Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CAPR
CUSIP: N/A
CIK: 1133869
Web: www.capricor.com
Phone: 310-358-3200
Fax: 415-875-7075
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $24.00
High Stock Price Target: $40.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +379.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.87)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,290,000.00
Net Margins: -88.52%
Pretax Margin: -88.52%
Return on Equity: -299.67%
Return on Assets: -45.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.63
Quick Ratio: 1.63

Sales & Book Value

Annual Sales: $25.18 million
Price / Sales: 6.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.73 per share
Price / Book: 6.86

Miscellaneous

Outstanding Shares: 31,503,000
Free Float: 27,723,000
Market Cap: $157.83 million
Optionable: Optionable
Beta: 3.99

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Frank I. Litvack M.D. (Age 59)
Independent Executive Chairman of the Board
Linda Marban Ph.D. (Age 51)
President, Chief Executive Officer, Director
Anthony Bergmann (Age 32)
Chief Financial Officer, Principal Accounting Officer
Karen G. Krasney J.D. (Age 62)
Executive Vice President, General Counsel
Thomas Lyle Copmann Ph.D. (Age 61)
Vice President - Regulatory Affairs and Drug Development
Houman Hemmati M.D.
Ph.D., Vice President - Medical & Clinical Development, New Therapies
Luis Rodriguez-Borlado Ph.D.
Vice President - Regenerative Therapies
Rachel Smith Ph.D. (Age 36)
Vice President - Research & Development
Deborah Ascheim M.D.
Chief Medical Officer
Joshua A. Kazam (Age 40)
Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CAPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Capricor Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CAPR shares.
View CAPR analyst ratings or view top-rated stocks.
What is Capricor Therapeutics' stock price target for 2024?: 2 brokerages have issued 1-year target prices for Capricor Therapeutics' stock. Their CAPR share price targets range from $8.00 to $40.00. On average, they predict the company's share price to reach $24.00 in the next year. This suggests a possible upside of 379.0% from the stock's current price.
View analysts price targets for CAPR or view top-rated stocks among Wall Street analysts.
How have CAPR shares performed in 2024?: Capricor Therapeutics' stock was trading at $4.89 at the beginning of the year. Since then, CAPR stock has increased by 2.5% and is now trading at $5.01.
View the best growth stocks for 2024 here.
When is Capricor Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CAPR earnings forecast.

How were Capricor Therapeutics' earnings last quarter?: Capricor Therapeutics Inc (NASDAQ:CAPR) released its earnings results on Thursday, February, 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.21. The biotechnology company had revenue of $12.09 million for the quarter, compared to analyst estimates of $5.80 million. Capricor Therapeutics had a negative net margin of 88.52% and a negative trailing twelve-month return on equity of 299.67%.
What other stocks do shareholders of Capricor Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).
How do I buy shares of Capricor Therapeutics?: Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CAPR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial